Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10)

Vaccine

Volumn 17, Issue 15-16, 1999, Pages 1951-1963

  Aurelian, L ^a,b,c   Kokuba, H ^a,b   Smith, C C ^a  

^a Dept Pharmacol Exp Therapeut U   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c AuRx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES SIMPLEX VACCINE;

ANIMAL CELL; ANTIBODY TITER; ARTICLE; DRUG EFFICACY; GENE DELETION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; IMMUNOGENICITY; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS MUTATION;

ANIMALS; ANTIBODIES, VIRAL; BLOTTING, WESTERN; CELL DIVISION; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; DEFECTIVE VIRUSES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GANGLIA; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 2, HUMAN; HUMANS; MICE; MICE, INBRED STRAINS; NEURONS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RIBONUCLEOTIDE REDUCTASES; SEQUENCE DELETION; T-LYMPHOCYTES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0033537972     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00470-8     Document Type: Article

References (45)

1. Fleming D.T., McQuillan G.M., Johnsons R.E., Nahmias A.J., Aral S.O., Lee F.K., St. Louis M.E. Herpes simplex virus type 2 in the US, 1976 to 1994. New Engl. J. Med. 337:1997;1105-1111.
2. Aurelian L. The role of immunosuppression in herpes simplex virus pathogenesis and its relationship to AIDS. In: Aurelian, L., editor. Herpesviruses, the immune system and AIDS. Boston, MA: Kluwer Academic Publishers, 1990. p. 139-69.
3. Wymer J.P., Chung T.D., Chang Y.N., Hayward G.S., Aurelian L. Identification of immediate-early type cis-response elements in the promoter for the ribonucleotide reductase large subunit from herpes simplex virus type 2. J. Virol. 63:1989;2773-2784.
4. Desai P., Ramakrishnan R., Lin Z.W., Osak B., Glorioso J.C., Levine M. The RR1 gene of herpes simplex virus type 1 is uniquely trans-activated by ICP0 during infection. J. Virol. 67:1993;6125-6135.
5. Zhu J., Aurelian L. AP-1 cis-response elements are involved in basal expression and Vmw110 transactivation of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP0). Virology. 231:1997;301-312.
6. Valyi-Nagy T., Deshmane S., Dillner A., Fraser N.W. Induction ofcellular transcription factors in trigeminal ganglia of mice by corneal scarification, herpes simplex virus type 1 infection, and explanation of trigeminal ganglia. J. Virol. 65:1991;4142-4152.
7. Tal-Singer R., Lasner T.M., Podrzucki W., Skokotas A., Laeary J.J., Berger S.L., Fraser N.W. Gene expression during reactivation of herpes simplex virus type 1 from latency in the peripheral nervous system is different from that during lytic infection of tissue cultures. J. Virol. 71:1997;5268-5276.
8. Aurelian L. Herpes simplex virus type 2: unique biological properties include neoplastic potential mediated by the PK domain of the large subunit of ribonucleotide reductase. In: Frontiers in Bioscience, 3, d237-249, PubMed No: 9459654, 1998. URL:http://bioscience.org/1998/v3/ d/aurelian/list.htm.
9. Goldstein D.J., Weller S.K. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis:isolation and characterization of an ICP6lacZ insertion mutant. J. Virol. 62:1988;196-205.
10. Idowu A.D., Fraser-Smith E.B., Paffenberger K.L., Herman R.C. Deletion of herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vitro. Antiviral Res. 17:1992;145-156.
11. Jacobson J.G., Leib D.A., Goldstein D.J., Bogard C.L., Schaffer P.A., Weller S.K., Coen D.M. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology. 173:1989;276-283.
12. Chung T.D., Wymer J.P., Smith C.C., Kulka M., Aurelian L. Protein kinase activity associated with the large subunit of the herpes simplex virus type ribonucleotide reductase (ICP10). J. Virol. 63:1989;3389-3398.
13. Nelson J.W., Zhu J., Smith C.C., Kulka M., Aurelian L. ATP and SH3 binding sites in the protein kinase of the large subunit of herpes simplex virus type 2 of ribonucleotide reductase (ICP10). J. Biol. Chem. 271:1996;17021-17027.
14. Peng T., Hunter J.R.C., Nelson J.W. The novel protein kinase of the RR1 subunit of herpes simplex virus has autophosphorylation and transphosphorylation activity that differs in its ATP requirements for HSV-1 and HSV-2. Virology. 216:1996;184-196.
15. Cooper J., Conner J., Clements J.B. Characterization of the novel protein kinase activity present in the R1 subunit of herpes simplex virus ribonucleotide reductase. J.Virol. 69:1995;4979-4985.
16. Smith C.C., Wymer J.P., Luo J.H., Aurelian L. Genomic sequences homologous to the protein kinase region of the bifunctional herpes simplex virus type 2 protein ICP10. Virus Genes. 5(3):1991;215-226.
17. Hayashi Y., Iwasaka T., Smith C.C., Aurelian L., Lewis G.K., Ts'o P.O.P. Multistep transformation by defined fragments of herpes simplex virus type 2 DNA: Oncogenic region and its gene product. Proc. Natl. Acad. Sci. 82:1985;8493-8497.
18. Smith C.C., Luo J.H., Hunter J.C.R., Ordonez J.V., Aurelian L. The transmembrane domain of the large subunit of HSV-2 ribonucleotide reductase (ICP10) is required for the transformation-related signaling pathways that involve ras activation. Virology. 200:1994;598-612.
19. Smith C.C., Peng T., Kulka M., Aurelian L. The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is involved in IE gene transcription and virus growth. J. Virol. 1998;72:9131-41.
20. Aurelian L., Terzano P., Smith C.C., Chung T.D., Shamsuddin A., Costa S., Orlandi C. Amino-terminal epitope of herpes simplex virus type 2 ICP10 protein as a molecular diagnostic marker for cervical intraepithelial neoplasia. Cancer Cells. 7:1989;187-191.
21. Manak M.M., Aurelian L., Ts'o P.O.P. Enhancement of focus formation in neoplastic transformation by early herpes simplex virus type 2 functions. J. Virol. 40:1981;289-300.
22. Smith C.C., Kulka M., Wymer J.P., Chung T.D., Aurelian L. Expression of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for virus growth and neoplastic transformation. J. Gen. Virol. 73:1992;1417-1428.
23. Wachsman M., Luo J.H., Aurelian L., Paoletti E. Protection from herpes simplex virus type 2 is associated with T-cells involved in delayed type hypersensitivity that recognize glycosylation-related epitopes on glycoprotein D. Vaccine. 10:1992;447-454.
24. Wachsman M., Aurelian L., Hunter J.C.R., Perkus M.E., Paoletti E. Expression of herpes simplex virus glycoprotein D on antigen presenting cells infected with vaccinia recombinants and protective immunity. Biosci. Rep. 8:1988;323-334.
25. Aurelian L. Herpes simplex viruses. In: Specter S., Lancz G., editors. Clinical virology manual. 2nd ed. NY: Elsevier Science Pub., 1992. p. 473-94.
26. Wilcox K.W., Kohn A., Sklyanskaya E., Roizman B. Herpes simplex virus phosphoproteins. I. Phosphate cycles on and off some viral polypeptides and can alter their affinity for DNA. J. Virol. 33:1980;167-182.
27. Read G.S., Karr B.M., Knight K. Isolation of herpes simplex virus type 1 mutant with a deletion in the virion host shutoff gene and identification of multiple forms of the vhs (UL41) polypeptide. J. Virol. 67:1993;7149-7160.
28. Meignier B., Jourdier T.M., Norrild B., Pereira L., Roizman B. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus. J. Inf. Dis. 155:1987;921-930.
29. Burke R.L. Current developments in herpes simplex virus vaccines. Semin. Virol. 4:1993;187-197.
30. Meignier B., Longnecker R., Mavroma-Nazos P., Sears A.E., Roizman B. Virulence and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1. Virology. 162:1988;251-254.
31. McDermott M.R., Smiley J.R., Leslie P., Brais J., Rudzroga H.E., Bienenstock J. Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J. Virol. 51:1984;747-773.
32. Aurelian L., Smith C.C., Wachsman M., Paoletti E. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D. Rev. Infect. Dis. 13 (Suppl 11):1991;924-934. (review).
33. Milligan G.N., Bernstein D.I., Bourne N. T-lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J. Immunol. 160:1998;6093-6100.
34. Ghiasi H., Cia S., Slanina S., Nesburn A.B., Wechsler S.L. Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge. Antiviral Res. 28:1995;147-157.
35. Da Costa X.J., Bourne N., Stanberry L.R., Knipe D.M. Construction and characterization of a replication-defective Herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology. 232:1997;1-12.
36. Spector F.C., Kern E.R., Palmer J., Kaiwar R., Cha T.-A., Brown P., Spaete R.R. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J. Inf. Dis. 177:1998;1143-1154.
37. McLean C.S., Erturk M., Jennings R., Ni Challanain D., Minson A.C., Duncan I., Boursnell M.E.G., Inglis S.C. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J. Inf. Dis. 170:1994;1100-1109.
38. Bruskin A., Jackson J., Bishop J.M., McCarley D.J., Schatzman R.C. Six amino acids from the retroviral gene gag greatly enhance the transforming potential of the oncogene v-erb-B. Oncogene. 5:1990;15-24.
39. Falcone G., Tato F., Alema S. Distinctive effects of the viral oncogenes myc, erb, fps and src on the differentiation program of quail myogenetic cells. Proc. Nat. Acad. Sci. USA. 82:1985;426-430.
40. Lee M.-S., Yang J.-H., Salehi Z., Arnstein P., Chen L.-S., Jay G., Rhim J.S. Neoplastic transformation of a human keratinocyte cell line by the v-fos oncogene. Oncogene. 8:1993;387-393.
41. Basolo F., Fiore L., Ciardiello F., Calvo S., Fontanini G., Conaldi P.G., Toniolo A. Response of normal and oncogene-transformed human mammary epithelial cells to transforming growth factor β1 (TGF-β1): lack of growth inhibitory effect on cells expressing the simian virus 40 large T-antigen. Int. J. Cancer. 56:1994;736-742.
42. Yang D., Kohler S.K., Maher V.M., McCormick J.J. v-sis oncogene-induced transformation of human fibroblasts into cells capable of forming benign tumors. Carcinogenesis. 15:1994;2167-2175.
43. Overton H., McMillan D., Hope L., Wong-Kai-In P. Production of host shutoff-defective mutants of herpes simplex virus type 1 by inactivation of the UL13 gene. Virology. 202:1994;97-106.
44. Lekstrom-Himes J.A., Pesnicak L., Straus S.E. The quantity of latent viral DNA correlates with the relative rates at which Herpes simplex virus types 1 and 2 cause recurrent genital outbreaks. J. Virol. 72:1998;2760-2764.
45. Lieb D.A., Coen D.M., Bograd C.L., Hicks K.A., Yager D.R., Knipe D.M., Tyler K.L., Schaffer P.A. Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J. Virol. 63:1989;759-768.